AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the findings from ENDEAVOR (NCT04986202).

ENDEAVOR is double-blind, randomized, placebo-controlled, phase 2b and phase 3 trial investigating the use of mitiperstat in patients with HFpEF and HFmrEF. 709 patients were randomized 1:1:1 to receive either mitiperstat 2.5 mg, 5 mg or placebo. Patients were followed-up from baseline to week 16 and week 24, and the primary outcome measures were the change from baseline of Kansas City Cardiomyopathy Questionnaire Total Symptom Score and six minute walk distance.

Interview Questions:
1.    What is the importance behind the ENDEAVOR trial?
2.    Could you tell us about the mechanism of action behind mitiperstat?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.